Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of marzeptacog alfa in patients factor VII deficiency, thrombasthenia receiving emicizumab (Hemlibra)

X
Trial Profile

Phase I/II study of marzeptacog alfa in patients factor VII deficiency, thrombasthenia receiving emicizumab (Hemlibra)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 12 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Marzeptacog alfa (Primary) ; Emicizumab
  • Indications Haemophilia; Thrombasthenia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Nov 2020 According to a Catalyst Pharmaceuticals media release, company anticipates to initiate this study by year end.
    • 10 Aug 2020 New trial record
    • 06 Aug 2020 According to a Catalyst Biosciences media release, the company is planning to initiate this study in late 2020 and timeline for this trial is subject to the readiness of trial sites and potential effects of COVID-19 on clinical trial execution.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top